Clinical investigations have demonstrated increased concentrations of various coagulation factors (e.g., FII, FX, FXII, prothrombin, and fibrinogen) in the blood or CSF of individuals diagnosed with MS [10,13–15]. This evidence concerns the gene F10 and myeloid sarcoma.